bluebird bio (LSE:0HOH) - Cotización, noticias y análisis

Resumen de acción 0HOH

bluebird bio, Inc. es una empresa de biotecnología que investiga, desarrolla y comercializa en Estados Unidos terapias génicas para curar enfermedades genéticas graves. Saber más

Análisis fundamental de 0HOH
Puntuación del snowflake
Valoración	5/6
Crecimiento futuro	2/6
Rendimiento pasado	0/6
Salud financiera	0/6
Dividendos	0/6

Recompensas

Cotiza un 95.8% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los ingresos de 41.53%

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

Los accionistas han sido diluidos sustancialmente en el último año

Tiene menos de 1 año de cash runway

Patrimonio neto negativo

Alta volatilidad del precio de la acción en los últimos 3 meses

+ 2 riesgos adicionales

Competidores de bluebird bio, Inc.

Arecor Therapeutics

AIM:AREC

UK£28.9m

Avacta Group

AIM:AVCT

UK£168.3m

Tissue Regenix Group

AIM:TRX

UK£41.0m

BSF Enterprise

LSE:BSFA

UK£3.0m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de bluebird bio
Precios históricos de las acciones
Precio actual de la acción	US$0.36
Máximo en las últimas 52 semanas	US$5.53
Mínimo de 52 semanas	US$0.29
Beta	0.80
1Cambio en 1 mes	-27.32%
Variación en 3 meses	-40.60%
Cambio de 1 año	-90.67%
3Variación en 3 años	-96.48%
Variación en 5 años	-99.52%
Variación desde la OPV	-99.82%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	0HOH	GB Biotechs	Mercado GB
7D	20.4%	1.5%	1.7%
1Y	-90.7%	-16.3%	8.4%

Rentabilidad vs. Industria: Los resultados de 0HOH fueron inferiores a los de la industria UK Biotechs, que obtuvo un rendimiento del -16.3% el año pasado.

Rentabilidad vs. Mercado: 0HOH obtuvo unos resultados inferiores a los del mercado UK, que fueron del 8.4% el año pasado.

Volatilidad de los precios

Is 0HOH's price volatile compared to industry and market?
0HOH volatility
0HOH Average Weekly Movement	12.9%
Biotechs Industry Average Movement	9.0%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Precio estable de las acciones: El precio de las acciones de 0HOH ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de 0HOH(13%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de UK.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1992	282	Andrew Obenshain	www.bluebirdbio.com

bluebird bio, Inc, empresa de biotecnología, investiga, desarrolla y comercializa en Estados Unidos terapias génicas para enfermedades genéticas graves curativas. Los productos candidatos de la empresa para enfermedades genéticas graves incluyen ZYNTEGLO (betibeglogene autotemcel) para el tratamiento de la ß-talasemia dependiente de transfusión; lovotibeglogene autotemcel para el tratamiento de la anemia falciforme (ECF); y SKYSONA (elivaldogene autotemcel) para tratar la adrenoleucodistrofia cerebral. Sus programas de desarrollo clínico incluyen HGB-205, HGB-206 y HGB-210 para evaluar la seguridad y eficacia de lovo-cel en el tratamiento de pacientes con ECF; y HGB-204, HGB-205, HGB-207 y HGB-212 para evaluar la seguridad y eficacia de beti-cel en el tratamiento de pacientes con ß-talasemia.

Resumen de fundamentos de bluebird bio, Inc.

¿Cómo se comparan los beneficios e ingresos de bluebird bio con su capitalización de mercado?
Estadísticas fundamentales de 0HOH
Capitalización bursátil	US$71.94m
Beneficios(TTM)	-US$292.82m
Ingresos (TTM)	US$53.12m

1.4x

Ratio precio-ventas (PS)

-0.2x

Ratio precio-beneficio (PE)

¿Está 0HOH sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 0HOH
Ingresos	US$53.12m
Coste de los ingresos	US$78.78m
Beneficio bruto	-US$25.66m
Otros gastos	US$267.16m
Beneficios	-US$292.82m

Últimos beneficios comunicados

Sep 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-1.51
Margen bruto	-48.31%
Margen de beneficio neto	-551.25%
Ratio deuda/patrimonio	-1,394.4%

¿Cómo se ha desempeñado 0HOH a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción 0HOH

Recompensas

Análisis de riesgos

Competidores de bluebird bio, Inc.

AIM:AREC

UK£28.9m

AIM:AVCT

UK£168.3m

AIM:TRX

UK£41.0m

LSE:BSFA

UK£3.0m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Third quarter 2024 earnings released: US$0.31 loss per share (vs US$0.66 loss in 3Q 2023)

Forecast to breakeven in 2026

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

Recent updates

Third quarter 2024 earnings released: US$0.31 loss per share (vs US$0.66 loss in 3Q 2023)

Forecast to breakeven in 2026

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

bluebird bio, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2024

bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024

bluebird bio, Inc. announced delayed 10-Q filing

Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Now 41% undervalued after recent price drop

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

New major risk - Shareholder dilution

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Revenue and earnings growth

Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels

Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events

New major risk - Share price stability

Third quarter 2023 earnings released: US$0.66 loss per share (vs US$0.94 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Now 20% undervalued after recent price drop

New minor risk - Insider selling

President recently sold US$60k worth of stock

Second quarter 2023 earnings released: US$0.67 loss per share (vs US$1.36 loss in 2Q 2022)

bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events

First quarter 2023 earnings released: EPS: US$0.21 (vs US$1.66 loss in 1Q 2022)

Full year 2022 earnings released: US$3.39 loss per share (vs US$8.17 loss in FY 2021)

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18

Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition

An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million.

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.94 loss per share (vs US$2.23 loss in 3Q 2021)

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer

bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. Announces Executive Changes

Treasurer recently sold US$78k worth of stock

bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

President recently sold US$96k worth of stock

Second quarter 2022 earnings released: US$1.36 loss per share (vs US$2.31 loss in 2Q 2021)

bluebird bio, Inc. Appoints Tom Klima as Chief Commercial & Operating Officer, Effective August 8, 2022

bluebird bio, Inc. Announces That the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee Recommends Approval of elivaldogene autotemcel (eli-cel) for the Treatment of Early Active Cerebral Adrenoleukodystrophy

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

Less than half of directors are independent

bluebird bio, Inc., Annual General Meeting, Jun 22, 2022

Bluebird Bio, Inc. Announces Executive Changes

bluebird bio, Inc. appoints Charlotte Jones-Burton as Class I director, effective March 7, 2022

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. Announces Resignation of Jessica Whitten as Chief Accounting Officer and Principal Accounting Officer

CEO & Director recently sold US$74k worth of stock

bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. to Launch Both beti-cel and eli-cel for Patients in the U.S. in Mid-2022